Drug
Venetoclax clinical trials
Also written ABT-199, GDC-0199, Venclexta and Venclyxto.
- studies test it
- 546
- open now
- 240
- in phase 3
- 51
- first study started
- 2010
Keep track of what changes. Save the venetoclax studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
541 studies that test it; most in 2024 (72); 5 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 5 |
| 2014 | 11 |
| 2015 | 6 |
| 2016 | 12 |
| 2017 | 34 |
| 2018 | 42 |
| 2019 | 46 |
| 2020 | 47 |
| 2021 | 40 |
| 2022 | 64 |
| 2023 | 52 |
| 2024 | 72 |
| 2025 | 50 |
| 2026 | 53 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 6
- Phase 1
- 234
- Phase 2
- 334
- Phase 3
- 51
- Phase 4
- 6
- No phase
- 25
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 122 · Other 424
M.D. Anderson Cancer Center (62) · AbbVie (53) · National Cancer Institute (NCI) (32) · Institute of Hematology & Blood Diseases Hospital, China (26) · The First Affiliated Hospital of Soochow University (17) · Dana-Farber Cancer Institute (15) · Hoffmann-La Roche (13) · City of Hope Medical Center (12)
Often tested with
Tested in the same studies.
Azacitidine (129) · Obinutuzumab (49) · Cytarabine (48) · Decitabine (35) · Ibrutinib (31) · Rituximab (27) · Dexamethasone (24) · Acalabrutinib (16)
Studies
Open first, then newest update. How each study uses venetoclax is read from its arms, and is right about nine times in ten.
Testing it · 546
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingPhase 2Fred Hutchinson Cancer CenterNCT04941716Written as Venetoclax
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingPhase 3National Cancer Institute (NCI)NCT04269902Written as Venetoclax
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Venetoclax
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingPhase 2AstraZenecaNCT07024706Written as Venetoclax
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as Venetoclax
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingPhase 1Roswell Park Cancer InstituteNCT07679334Written as Venetoclax
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Venetoclax
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Venetoclax
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Venetoclax
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT07437950Written as Venetoclax
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT06954987Written as Venetoclax
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as Venetoclax
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingPhase 2OHSU Knight Cancer InstituteNCT07228273Written as Venetoclax
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingPhase 1Northside Hospital, Inc.NCT07511062Written as Venetoclax
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2RecruitingPhase 3University of UlmNCT04628026Written as Venetoclax
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as Venetoclax
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Venetoclax
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07159620Written as VEN (Venetoclax)
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07133997Written as Venetoclax
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruitingPhase 1Montefiore Medical CenterNCT05986240Written as Danvatirsen + Venetoclax
See all 546 studies that test venetoclax →
Given in every arm · 108 — venetoclax is usual care beside what is tested
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesRecruitingPhase 1/2Nurix Therapeutics, Inc.NCT07520006Written as venetoclax
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)RecruitingPhase 2/3AbbVieNCT07581002Written as Venetoclax
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06317649Written as Venetoclax
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingPhase 3Merck Sharp & Dohme LLCNCT05947851Written as Venetoclax
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Venetoclax
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06672146Written as Venetoclax
- Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLRecruitingPhase 2Beijing 302 HospitalNCT07078591Written as Venetoclax
- Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT00501826Written as Venetoclax
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingPhase 3PETHEMA FoundationNCT07478991Written as Venetoclax
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Venetoclax
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT06763341Written as Venetoclax
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 3Janssen Research & Development, LLCNCT06852222Written as Venetoclax (VEN)
- Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1Jennifer SaultzNCT03874052Written as Venetoclax
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Venetoclax
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)RecruitingPhase 1Kittika PoonsombudlertNCT07177079Written as Venetoclax
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingPhase 3German CLL Study GroupNCT05197192Written as Venetoclax
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07495631Written as Venetoclax
- Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AMLNot yet recruitingPhase 3Ruijin HospitalNCT07735117Written as Venetoclax
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaRecruitingPhase 2The Lymphoma Academic Research OrganisationNCT06558604Written as Venetoclax Oral Product
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Venetoclax
Showing 20 of 108.
As the comparator · 10 — what is tested is compared with venetoclax
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3BeOne MedicinesNCT06943872Written as Venetoclax
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingPhase 3BeOne MedicinesNCT06846671Written as Venetoclax
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as Venetoclax
- Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06532552Written as VA
- Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingPhase 3Ruijin HospitalNCT06496308Written as Venetoclax
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 3BeOne MedicinesNCT06073821Written as Venetoclax
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Venetoclax
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Venetoclax
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnPhase 2University of FloridaNCT05766514Written as Venetoclax
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedPhase 3Gilead SciencesNCT04778397Written as Venetoclax
Codes
What other systems call venetoclax · ClinicalTrials.gg INT006262
- MeSH (NLM) C579720venetoclaxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) N54AIC43PWVENETOCLAXConfirmed FDA, NLM, Wikidata
- RxNorm 1747556Confirmed FDA, Wikidata
- Wikidata Q23671272venetoclaxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103147VenetoclaxOne source FDA
- DrugBank DB11581One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579720 | venetoclax | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | N54AIC43PW | VENETOCLAX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1747556 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23671272 | venetoclax | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103147 | Venetoclax | One source FDA |
| DrugBank | DB11581 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.